title: [Recent advances in type 2 diabetes mellitus].
abstract: Currently, the oral glucose tolerance test remains the "gold standard" for diagnosing type 2 diabetes, HbA (1c) being of subordinate value because of its limited diagnostic sensitivity. Fully evaluated risk scores and questionnaires are helpful in determining individual type 2 diabetes risk profiles and may prove valuable tools in preventing this type of diabetes. Genetic studies support our current understanding of the pathophysiology of type 2 diabetes. In the near future genetic data may become useful in optimizing individual preventative and therapeutic strategies. Recent data suggest that it is reasonable to adjust therapeutic aims on the specific situation of individual patients for achieving optimal results. The present therapeutic armamentarium for the treatment of type 2 diabetes has been rapidly extended over the recent years. To deal with this situation, pharmacovigilance is an essential tool to ensure drug safety and improve existing therapeutic standards.
authors: Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl-Gustav-Carus der technischen Universität Dresden, Bochum. Andreas.Barthel@endokrinologikum.com
authors: A
authors: A
authors: Barthel
authors: H
authors: H
authors: Rietzsch
authors: S R
authors: SR
authors: Bornstein
authors: P
authors: P
authors: Schwarz
mesh_terms: D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / Q000235:genetics; D003692:Delayed-Action Preparations; D048909:Diabetes Complications / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives / Q000627:therapeutic use; D007333:Insulin Resistance / Q000502:physiology; D024821:Metabolic Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D009765:Obesity / Q000150:complications; D011110:Polymorphism, Genetic / Q000235:genetics; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000073940:Transcription Factor 4; D058118:Transcription Factor 7-Like 2 Protein / Q000235:genetics; D014157:Transcription Factors / Q000235:genetics
chemical_list: D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; D003692:Delayed-Action Preparations; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000073940:Transcription Factor 4; D058118:Transcription Factor 7-Like 2 Protein; D014157:Transcription Factors; C532096:TCF4 protein, human; C544894:TCF7L2 protein, human; C517652:hemoglobin A1c protein, human